Remove 2029 Remove Biosimilars Remove Drug Pricing
article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

“The dominance of the US within the 7MM is due to its larger insomnia population and higher drug prices. GlobalData considered drug pricing and market exclusivity to be two major obstacles. GlobalData considered drug pricing and market exclusivity to be two major obstacles.

article thumbnail

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

FDA Law Blog: Biosimilars

The manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug. The primary manufacturer of a selected drug may also request CMS to terminate its agreement if they are unwilling to participate in the Medicare Drug Price Negotiation.

Labelling 105
article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

Biosimilars and generics flood the market upon patent loss, which exerts pricing pressure on the branded product. There has been a push by the Trump administration to increase biosimilar and generic drug use in the US. Biosimilars and generics can be as much as 80% cheaper than branded alternatives.